Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393–401.

Article  CAS  PubMed  Google Scholar 

Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281–357.

Article  CAS  PubMed  Google Scholar 

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–104.

Article  PubMed  Google Scholar 

Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;391:2335–45.

Article  PubMed  Google Scholar 

Azizi M, Saxena M, Wang Y, Jenkins JS, Devireddy C, Rader F, et al. Endovascular ultrasound renal denervation to treat hypertension: the RADIANCE II randomized clinical trial. JAMA. 2023;329:651–61.

Article  PubMed  PubMed Central  Google Scholar 

Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390:2160–70.

Article  PubMed  Google Scholar 

Kandzari DE, Bohm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391:2346–55.

Article  PubMed  Google Scholar 

Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 2021;397:2476–86.

Article  CAS  PubMed  Google Scholar 

Kario K, Mahfoud F, Kandzari DE, Townsend RR, Weber MA, Schmieder RE, et al. Long-term reduction in morning and nighttime blood pressure after renal denervation: 36-month results from SPYRAL HTN-ON MED trial. Hypertens Res. 2023;46:280–8.

Article  CAS  PubMed  Google Scholar 

Kario K, Yokoi Y, Okamura K, Fujihara M, Ogoyama Y, Yamamoto E, et al. Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial. Hypertens Res. 2022;45:221–31.

Article  PubMed  Google Scholar 

Mancia G, Kreutz R, Brunstrom M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41:1874–2071.

Article  CAS  PubMed  Google Scholar 

Schmieder RE, Jumar A, Fronk EM, Alexandre AF, Bramlage P. Quality of life and emotional impact of a fixed-dose combination of antihypertensive drugs in patients with uncontrolled hypertension. J Clin Hypertens (Greenwich). 2017;19:126–34.

Article  PubMed  Google Scholar 

Croog SH, Levine S, Testa MA, Brown B, Bulpitt CJ, Jenkins CD, et al. The effects of antihypertensive therapy on the quality of life. N. Engl J Med. 1986;314:1657–64.

Article  CAS  PubMed  Google Scholar 

Bremner AD. Antihypertensive medication and quality of life–silent treatment of a silent killer? Cardiovasc Drugs Ther. 2002;16:353–64.

Article  PubMed  Google Scholar 

Mena-Martin FJ, Martin-Escudero JC, Simal-Blanco F, Carretero-Ares JL, Arzua-Mouronte D, Herreros-Fernandez V. Health-related quality of life of subjects with known and unknown hypertension: results from the population-based Hortega study. J Hypertens. 2003;21:1283–9.

Article  CAS  PubMed  Google Scholar 

Saito I, Saruta T. Effect of education through a periodic newsletter on persistence with antihypertensive therapy. Hypertens Res. 2003;26:159–62.

Article  PubMed  Google Scholar 

Yoshida K, Matsuoka H, Omae T, Fujii J. Patient-hospital relationship and quality of life in elderly patients with hypertension. Hypertens Res. 1995;18:77–83.

Article  CAS  PubMed  Google Scholar 

Kario K, Kai H, Nanto S, Yokoi H. Anti-hypertensive medication adherence in the REQUIRE trial: post-hoc exploratory evaluation. Hypertens Res. 2023;46:2044–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011;57:1076–80.

Article  CAS  PubMed  Google Scholar 

Kario K, Okura A, Okawara Y, Tomitani N, Ikemoto T, Hoshide S. Impact of introducing catheter-based renal denervation into Japan for hypertension management: Estimation of number of target patients and clinical relevance of ambulatory blood pressure reduction. Curr Hypertens Rev. 2016;12:156–63.

Okamura K, Shirai K, Okuda T, Urata H. The prevalence of Japanese outpatients with hypertension who meet the definition of treatment resistant hypertension and are eligible for enrolment in clinical trials of endovascular ultrasound renal denervation. Intern Med. 2018;57:1–12.

Article  CAS  PubMed  Google Scholar 

Okamura K, Yano Y, Takamiya Y, Shirai K, Urata H. Efficacy and safety of a combination antihypertensive drug (olmesartan plus azelnidipine): “Issues with hypertension studies in real-world practice”. Clin Exp Hypertens. 2020;42:438–48.

Article  CAS  PubMed  Google Scholar 

Okamura K, Shirai K, Miyazaki M, Okuda T, Takamiya Y, Goto M, et al. Investigation of a dipeptidyl peptidase-4 inhibitor/thiazolidinedione combination drug for patients with type 2 diabetes and poor glycemic control: difficulty with patient enrollment. J Clin Med Res. 2019;11:89–97.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Okamura K, Shirai K, Totake N, Okuda T, Urata H. Prospective direct comparison of antihypertensive effect and safety between high-dose amlodipine or indapamide in hypertensive patients uncontrolled by standard doses of angiotensin receptor blockers and amlodipine. Clin Exp Hypertens. 2018;40:99–106.

Article  CAS  PubMed  Google Scholar 

Okamura K, Okuda T, Kumagai N, Mitsutake R, Urata H. CHAT-E i: antihypertensive effect and safety of a candesartan/hydrochlorothiazide combination in patients with uncontrolled hypertension. Therapeutic Res. 2015;36:439–48.

Google Scholar 

Azizi M, Sharp ASP, Fisher NDL, Weber MA, Lobo MD, Daemen J, et al. Patient-level pooled analysis of endovascular ultrasound renal denervation or a sham procedure at 6 months following medication escalation: The RADIANCE Clinical Trial Program. Circulation. 2024;149:747-759.

Miura K, Nagai M, Ohkubo T. Epidemiology of hypertension in Japan: where are we now? Circ J. 2013;77:2226–31.

Article  PubMed  Google Scholar 

Chowdhury EK, Reid CM, Zomer E, Kelly DJ, Liew D. Cost-effectiveness of renal denervation therapy for treatment-resistant hypertension: a best case scenario. Am J Hypertens. 2018;31:1156–63.

Article  PubMed  Google Scholar 

Kario K, Kagitani H, Hayashi S, Hanamura S, Ozawa K, Kanegae H. A Japan nationwide web-based survey of patient preference for renal denervation for hypertension treatment. Hypertens Res. 2022;45:232–40.

Article  PubMed  Google Scholar 

Zhang Z, Zhang X, Ye R, Li X, Chen X. Patient preference for renal denervation therapy in hypertension: a cross-sectional survey in Chengdu, China. Hypertens Res. 2022;45:954–61.

Article  PubMed  Google Scholar 

Schmieder RE, Hogerl K, Jung S, Bramlage P, Veelken R, Ott C. Patient preference for therapies in hypertension: a cross-sectional survey of German patients. Clin Res Cardiol. 2019;108:1331–42.

Article  PubMed  Google Scholar 

Kresoja KP, Rommel KP, Fengler K, von Roeder M, Besler C, Lucke C, et al. Renal sympathetic denervation in patients with heart failure with preserved ejection fraction. Circ Heart Fail. 2021;14:e007421.

Article  CAS  PubMed  Google Scholar 

Kase M, Fujiki S, Kashimura T, Okura Y, Kodera K, Watanabe H, et al. Relationship between medical therapy, long-term care insurance, and comorbidity in elderly patients with heart failure with systolic dysfunction. Circ J. 2023;87:1130–7.

Article  CAS  PubMed  Google Scholar 

Kewcharoen J, Vutthikraivit W, Rattanawong P, Prasitlumkum N, Akoum NW, Bunch TJ, et al. Renal sympathetic denervation in addition to pulmonary vein isolation reduces the recurrence rate of atrial fibrillation: an updated meta-analysis of randomized control trials. J Inter Card Electrophysiol. 2021;60:459–67.

Article  Google Scholar 

Heradien M, Mahfoud F, Greyling C, Lauder L, van der Bijl P, Hettrick DA, et al. Renal denervation prevents subclinical atrial fibrillation in patients with hypertensive heart disease: Randomized, sham-controlled trial. Heart Rhythm. 2022;19:1765–73.

Article  PubMed  Google Scholar 

Hawson J, Harmer JA, Cowan M, Virk S, Campbell T, Bennett RG, et al. Renal denervation for the management of refractory ventricular arrhythmias: a systematic review. JACC Clin Electrophysiol 2021;7:100–8.

Article  PubMed  Google Scholar 

Kario K, Hettrick DA, Prejbisz A, Januszewicz A. Obstructive sleep apnea-induced neurogenic nocturnal hypertension: a potential role of renal denervation? Hypertension. 2021;77:1047–60.

Article  CAS  PubMed  Google Scholar 

Kou C, Zhao X, Lin X, Fan X, Wang Q, Yu J. Effect of different treatments for obstructive sleep apnoea on blood pressure. J Hypertens. 2022;40:1071–84.

Article  CAS  PubMed